{
  "id": 5052,
  "text": "# NCCN Guidelines Version 1.2022 宫颈癌 宫颈癌的系统治疗a <html><body><table><tr><td colspan=\"4\">鳞状细胞癌、腺癌或腺鳞癌</td></tr><tr><td>放化疗</td><td colspan=\"3\">复发或转移性疾病</td></tr><tr><td>首选方案</td><td>一线联合治疗b， 首选方案</td><td>可选的一线单药治疗c 首选方案</td><td>二线或后续治疗： 首选方案</td></tr><tr><td rowspan=\"4\">·顺铂 ·卡铂（如果不能 耐受顺铂)</td><td rowspan=\"4\">·帕博利珠单抗+顺铂/紫杉醇土贝伐珠单抗 （适用于PD-L1阳性肿瘤）（1类）d,e,f.",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: # NCCN Guidelines Version 1.2022 宫颈癌 宫颈癌的系统治疗a <html><body><table><tr><td colspan=\"4\">鳞状细胞癌、腺癌或腺鳞癌</td></tr><tr><td>放化疗</td><td colspan=\"3\">复发或转移性疾病</td></tr><tr><td>首选方案</td><td>一线联合治疗b， 首选方案</td><td>可选的一线单药治疗c 首选方案</td><td>二线或后续治疗： 首选方案</td></tr><tr><td rowspan=\"4\">·顺铂 ·卡铂（如果不能 耐受顺铂)</td><td rowspan=\"4\">·帕博利珠单抗+顺铂/紫杉醇土贝伐珠单抗 （适用于PD-L1阳性肿瘤）（1类）d,e,f.\n\n<question>: \n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n",
  "ChatGPT_response_0": "对于复发或转移性宫颈癌，首选的一线联合治疗方案包括帕博利珠单抗与顺铂或紫杉醇联合使用，加入贝伐珠单抗，适用于PD-L1阳性肿瘤患者。这种方案通过结合免疫治疗和化疗药物，有效提高治疗效果。",
  "query": "对于复发或转移性宫颈癌，哪些方案被推荐作为首选的一线联合治疗？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 对于复发或转移性宫颈癌，哪些方案被推荐作为首选的一线联合治疗？\n\n<reference text>: # NCCN Guidelines Version 1.2022 宫颈癌 宫颈癌的系统治疗a <html><body><table><tr><td colspan=\"4\">鳞状细胞癌、腺癌或腺鳞癌</td></tr><tr><td>放化疗</td><td colspan=\"3\">复发或转移性疾病</td></tr><tr><td>首选方案</td><td>一线联合治疗b， 首选方案</td><td>可选的一线单药治疗c 首选方案</td><td>二线或后续治疗： 首选方案</td></tr><tr><td rowspan=\"4\">·顺铂 ·卡铂（如果不能 耐受顺铂)</td><td rowspan=\"4\">·帕博利珠单抗+顺铂/紫杉醇土贝伐珠单抗 （适用于PD-L1阳性肿瘤）（1类）d,e,f.\n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n\n<reply>: ",
  "response": "对于复发或转移性宫颈癌，首选的一线联合治疗方案包括帕博利珠单抗与顺铂或紫杉醇联合使用，加入贝伐珠单抗，适用于PD-L1阳性肿瘤患者。这种方案通过结合免疫治疗和化疗药物，有效提高治疗效果。"
}